Jazz Pharmaceuticals JAZZ Increase (Decrease) in Inventories
Increase (Decrease) in Inventories at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's increase (decrease) in inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's increase (decrease) in inventories?
- Jazz Pharmaceuticals (JAZZ) reported increase (decrease) in inventories of $77.8M in Q1 2026.
- How has Jazz Pharmaceuticals's increase (decrease) in inventories changed year-over-year?
- Jazz Pharmaceuticals's increase (decrease) in inventories increased by 118.5% year-over-year, from $35.6M to $77.8M.
- What is the long-term trend for Jazz Pharmaceuticals's increase (decrease) in inventories?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's increase (decrease) in inventories has grown at a 17.7% compound annual growth rate (CAGR), from $48.86M to $93.76M.
- What does increase (decrease) in inventories mean?
- The change in the total value of products and materials the company has in stock.
- How do you interpret increase (decrease) in inventories?
- An increase may signal anticipation of higher sales or potential overproduction, while a decrease may indicate strong sales or supply chain constraints.
- How does increase (decrease) in inventories compare across companies?
- Highly dependent on industry-specific supply chain cycles; pharmaceutical peers often hold significant inventory to ensure product availability.